10-K/A XBRL

AMENDMENT NO. 1

Company: NRX Pharmaceuticals, Inc.
Filed: May 14, 2021
Period of Report: December 31, 2020
Accession Number: 0001654954-21-005637

View Document ↗ View on SEC.gov ↗